Mycoplasma Detection

Comprehensive Mycoplasma Detection and Testing Services – Ensuring Biopharmaceutical Safety and Regulatory Compliance

The rigorous detection of Mycoplasma contamination is an indispensable quality control measure in biopharmaceutical manufacturing, cell therapy development, vaccine production, and biomedical research. Mycoplasmas are among the smallest self‑replicating prokaryotes, lacking a cell wall, rendering them resistant to many common antibiotics and capable of passing through standard sterile filtration membranes. Their presence in cell cultures or biological products can alter cellular metabolism, gene expression, and immunogenicity, leading to unreliable experimental results, compromised product safety, and severe regulatory repercussions. Regulatory authorities including the US Pharmacopoeia (USP), European Pharmacopoeia (EP), Japanese Pharmacopoeia (JP), and the Chinese Pharmacopoeia (ChP) mandate stringent testing for Mycoplasma in all biological products intended for human use. However, the practical performance of a Mycoplasma testing strategy is not defined by a single method; it is critically dependent on the sample matrix, the expected Mycoplasma species, the sensitivity required, the time‑to‑result, and the specific regulatory pathway. Routine culture‑based methods, while recognised as the gold standard, are time‑consuming (up to 28 days) and may fail to detect fastidious or non‑cultivable strains. Consequently, a comprehensive testing programme must integrate multiple orthogonal approaches – including culture methods, DNA staining (indirect detection), and nucleic acid amplification techniques (NAT) such as real‑time PCR – to ensure the highest level of confidence. Our ISO/IEC 17025‑accredited and GMP‑compliant laboratory offers a fully integrated Mycoplasma testing platform, covering all validated methods prescribed by international pharmacopoeias, alongside advanced rapid alternatives for expedited product release. We deliver quantitative, traceable data, expert interpretation, and full compliance support, enabling you to meet regulatory requirements and ensure the safety of your products.

1. The Critical Need for Reliable Mycoplasma Testing – Scientific and Regulatory Rationale

Mycoplasmas are ubiquitous environmental contaminants that can be introduced into cell cultures through raw materials, laboratory personnel, or contaminated reagents. Over 20 species have been isolated from cell cultures, with M. orale, M. hyorhinis, M. arginini, M. fermentans, and A. laidlawii being the most frequently encountered. The consequences of undetected contamination are profound: altered cell growth, chromosomal aberrations, changes in metabolic activity, and modulation of viral production, which can compromise the integrity of biological products and lead to batch rejection or, worse, patient safety issues. Regulatory guidelines (e.g., USP <63>, EP 2.6.7, and ICH Q5A) require a clear demonstration of the absence of Mycoplasma in master cell banks, working cell banks, and final products. The choice of testing method – whether direct and indirect cultivation, fluorescence staining (Hoechst or DAPI), or validated NAT (PCR) – must be tailored to the sample type, the volume available, and the required sensitivity (typically < 10 CFU/mL for spiked samples). Our service begins with a comprehensive consultation to design a risk‑based testing strategy that balances speed, sensitivity, and regulatory acceptance for your specific product.

2. Our Multi‑Method Mycoplasma Testing Platform – Comprehensive and Flexible

We maintain a complete suite of pharmacopoeial and rapid methods for Mycoplasma detection, all performed under strictly controlled environmental conditions (including ISO 5/Class 100 environments) and with validated positive controls for relevant species. Our portfolio includes:

2.1 Culture‑Based Methods – Direct and Indirect Cultivation
We perform the gold‑standard culture assay according to USP <63> and EP 2.6.7, using both liquid media (e.g., Friis broth, SP‑4 broth) and solid agar plates. Samples are inoculated and incubated for up to 28 days, with subculturing and monitoring for characteristic “fried‑egg” colonies. Our protocol includes direct cultivation (for samples with low toxicity) and indirect cultivation (with a Vero cell monolayer to amplify slow‑growing species). We provide a final report of “no growth” after the full incubation period, with the limit of detection validated to < 10 CFU/mL for representative species.

2.2 DNA Staining (Fluorescence Microscopy) – Hoechst and DAPI Methods
For a rapid (< 24 hour) screening, we employ DNA‑binding fluorescent dyes (Hoechst 33258 or DAPI) to detect extranuclear DNA indicative of Mycoplasma contamination in cell culture supernatants or monolayer samples. This method is particularly useful for early‑warning screening and for samples where time is critical, and it can be performed in parallel with the culture assay for enhanced confidence.

2.3 Nucleic Acid Amplification (NAT) – Real‑Time PCR and Droplet Digital PCR (ddPCR)
We utilise validated real‑time PCR targeting the highly conserved 16S rRNA gene region (or the 16S‑23S rRNA spacer) for universal detection of over 60 Mycoplasma species. Our assay is fully validated according to ICH Q2(R1) and includes an internal control to monitor for inhibition. We offer qualitative (presence/absence) and quantitative (copy number) outputs, with a detection limit as low as < 10 genomic copies per reaction. For absolute quantification and for samples with complex matrices, we also offer droplet digital PCR (ddPCR) providing superior precision without requiring a standard curve. Results are available within 4‑6 hours of sample receipt, enabling rapid product release.

2.4 Integrated Testing Strategy – Combining Methods for Optimal Confidence
We recommend a combined approach where NAT is used for routine release (due to its speed and sensitivity), while culture and/or DNA staining are performed for cell bank characterisation and for orthogonal confirmation of any positive results. Our experts can design a customised testing scheme that aligns with your regulatory submission strategy and risk profile.

3. Advanced Capabilities – Method Development, Validation, and Matrix Suitability

For clients dealing with complex formulations, novel cell types, or advanced therapeutic products (e.g., CAR‑T cells, viral vectors, lipid nanoparticles), we offer a suite of customised research‑grade services that go beyond routine testing:

3.1 Matrix Validation and Inhibition Studies
We systematically assess the inhibition of NAT caused by residual media components, cryoprotectants, or purification additives. We perform spike‑and‑recovery experiments at two different levels (e.g., 10–100 CFU/mL) to confirm that the assay remains sensitive and accurate in your specific matrix. If inhibition is observed, we develop tailored sample pre‑treatment (dilution, extraction, or clean‑up) to eliminate interference.

3.2 Mycoplasma Species Identification – Sequencing and Species‑Specific PCR
In the event of a positive NAT result, we can perform amplicon sequencing or species‑specific PCR to identify the contaminating species. This is critical for source tracking and for designing effective decontamination protocols.

3.3 Accelerated and Automated High‑Throughput Screening
For large‑scale manufacturing, we offer automated NAT platforms capable of processing up to 384 samples per run, combined with automated data analysis and flagging of positive results. This is particularly valuable for monitoring multiple harvests, in‑process samples, and environmental monitoring.

3.4 Long‑Term Stability and Archive Testing
We provide stability studies to verify that Mycoplasma contamination does not emerge over the shelf life of your product, and we offer archive testing for cell banks and raw materials to ensure long‑term security.

3.5 Regulatory Support and Submission Assistance
Our team includes experts who have contributed to regulatory submissions for cell therapy and biologics. We can provide validation summary reports, method suitability statements, and risk assessment documents that are directly usable for FDA, EMA, and other agency filings.

4. Data Integrity, Standardisation, and Comprehensive Reporting

All analyses are conducted under a strict quality management system that includes the use of certified reference strains, regular participation in proficiency testing (e.g., UK NEQAS, FAPAS), and full traceability of all reagents and procedures. Our reports deliver:

• Full method description – including media formulations, incubation conditions, PCR primers/probes, and instrument settings.
• Detailed results – for culture: growth/no growth, with observed colony morphology; for DNA staining: microscopic evaluation with images; for NAT: Ct values, copy numbers (if quantified), and interpretation as negative, positive, or equivocal.
• Validation summary – including LOD, linearity, recovery rates, and any matrix effects.
• Interpretative comments – on the significance of the results, potential impact on product quality, and recommended actions.

Our reports are authored by senior microbiologists and molecular biologists who provide not just data, but actionable insights to guide your quality decisions.

Turnaround times: 4‑6 hours for NAT screening, 24‑48 hours for DNA staining, and 28 days for the complete culture assay (with interim negative reports after 14 and 21 days). Express services are available for emergency release.

5. Our Unmatched Expertise – Why Choose Our Laboratory for Mycoplasma Testing

We are one of the few laboratories that hold ISO/IEC 17025 accreditation and GMP compliance for the full suite of Mycoplasma detection methods prescribed by USP, EP, and JP. Our integrated infrastructure combines traditional culture, fluorescence microscopy, and advanced molecular platforms (qPCR, ddPCR) – enabling method triangulation and rapid resolution of ambiguous results. Our team comprises PhD‑level microbiologists, molecular scientists, and regulatory experts with decades of experience in the biologics industry, and we have a proven track record of supporting successful regulatory submissions for cell therapies, gene therapies, and vaccine products.

We offer unparalleled flexibility: we accept all sample types – from cell supernatants, frozen cell pellets, and viral harvests to formulated drug products and raw materials. We provide customised sampling kits with stabilising media to preserve sample integrity during transit. Our secure online portal enables real‑time tracking, access to raw data, and downloadable certificates.

Our modular pricing ensures cost‑effectiveness: you select the level of analysis – from a rapid NAT screen to full pharmacopoeial characterisation – with discounts for routine monitoring programmes and bulk submissions. We also provide training, method transfer, and technical consultancy to help you build or strengthen your internal Mycoplasma testing capabilities.

With a proven history of serving over 100 biopharmaceutical and cell therapy companies, we have enabled our partners to achieve regulatory confidence, ensure product safety, and accelerate time‑to‑market. We invite you to leverage our expertise for your Mycoplasma testing needs.

Contact our technical experts today to discuss your sample types, regulatory requirements, and desired turn‑around times. We will design a tailored testing plan and provide a detailed proposal within one business day.